| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA657: Carfilzomib for previously treated multiple myeloma and TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma |
|
Medicine details |
|
| Medicine name | carfilzomib (Kyprolis®) |
| Formulation | 60 mg powder for solution for infusion |
| Reference number | 3155 |
| Indication | In combination with either lenalidomide and dexamethasone or dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/08/2016 |
| NICE guidance | |
| Commercial arrangement | PAS |